BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relative Bioavailability
Conditions
Relative Bioavailability
Trial Timeline
May 16, 2019 → Sep 10, 2019
NCT ID
NCT03934333About BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg is a phase 1 stage product being developed by AstraZeneca for Relative Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT03934333. Target conditions include Relative Bioavailability.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03934333 | Phase 1 | Completed |
Competing Products
6 competing products in Relative Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab + Sonelokimab | MoonLake Immunotherapeutics | Phase 1 | 28 |
| ABT-333 | AbbVie | Phase 1 | 33 |
| D1400147 + D14000136 + D14000137 + Epanova® | AstraZeneca | Phase 1 | 33 |
| Ropivacaine 0.1% + Ropivacaine 0.4% | Baxter | Approved | 82 |
| Sulfatinib T capsule + Sulfatinib R capsule | HUTCHMED | Phase 1 | 28 |
| Tebipenem tablet form | Spero Therapeutics | Phase 1 | 25 |